Refining Incidence and Characteristics of Inflammatory Myopathies: A Quadruple-Source Capture-Recapture Survey Using the 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
10 2023
Historique:
revised: 31 03 2023
received: 29 07 2022
accepted: 11 05 2023
medline: 29 9 2023
pubmed: 16 5 2023
entrez: 16 5 2023
Statut: ppublish

Résumé

Inflammatory myopathies (IM), characterized by muscle inflammation and weakness, are rare systemic diseases. Our previous study estimated an IM incidence rate of 7.98 cases per million people per year (95% confidence interval 7.38-8.66) and highlighted important variations that were likely because of methodologic issues rather than true epidemiologic differences. In this study, we aimed to refine the incidence of IM, using the 2017 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for IM and a quadruple-source capture-recapture method during a 6-year period in Alsace, France, a region with a population of 2 million having benefits of good access to health care and accredited IM referral centers. Clinical data of potential IM patients were obtained from 4 sources (general practitioners and community specialists, public and private hospital records, public and private laboratories, and archives from the pathology department). Patients residing in Alsace and who fulfilled the 2017 EULAR/ACR criteria for IM between January 1, 2006, and January 1, 2013, were included. We corrected potentially incomplete ascertainment of cases with capture-recapture analyses. We studied both spatial and temporal distributions of incidence of IM. We also assessed systemic manifestations of the disease. Our review of 1,742 potential cases identified 106 patients with IM. No spatial or temporal heterogeneity was observed. Use of log-linear models showed an estimated 14.9 additional missed cases. Thus, the incidence rate of IM was 8.22 new cases per million inhabitants per year (95% confidence interval 6.76-9.69). Extramuscular manifestations other than dermatomyositis rash were frequently recorded. The stringent methodology used in our study provides an accurate estimation of the incidence of IM. This study also demonstrates, in a population-based cohort, the systemic nature of IM.

Identifiants

pubmed: 37192377
doi: 10.1002/art.42561
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1850-1855

Informations de copyright

© 2023 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

Références

Meyer A, Lannes B, Goetz J, et al. Inflammatory myopathies: a new landscape. Joint Bone Spine 2018;85:23-33.
Meyer A, Meyer N, Schaeffer M, et al. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford) 2015;54:50-63.
Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 2017;69:2271-82.
Parker MJ, Oldroyd A, Roberts ME, et al. Increasing incidence of adult idiopathic inflammatory myopathies in the City of Salford, UK: a 10-year epidemiological study. Rheumatol Adv Pract 2018;2:rky035.
Wittes JT, Colton T, Sidel VW. Capture-recapture methods for assessing the completeness of case ascertainment when using multiple information sources. J Chronic Dis 1974;27:25-36.
Meyer A, Chifflot H, Chatelus E, et al. Brief Report: spatial heterogeneity of systemic sclerosis in France: high prevalence in the northeast region. Arthritis Rheumatol 2016;68:1731-7.
Hook EB, Regal RR. Capture-recapture methods in epidemiology: methods and limitations. Epidemiol Rev 1995;17:243-64.
Kuo CF, See LC, Yu KH, et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 2011;165:1273-9.
Yu KH, See LC, Kuo CF, et al. Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan. Arthritis Care Res (Hoboken) 2013;65:244-50.
Carey IM, Banchoff E, Nirmalananthan N, et al. Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: a retrospective study using primary care data. PLoS One 2021;16:e0261983.
Svensson J, Arkema EV, Lundberg IE, et al. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatology (Oxford) 2017;56:802-10.
Chinoy H, Adimulam S, Marriage F, et al. Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann Rheum Dis 2012;71:961-5.
Love LA, Weinberg CR, McConnaughey DR, et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum 2009;60:2499-504.
Vegosen LJ, Weinberg CR, O'Hanlon TP, et al. Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis Rheum 2007;56:2719-28.
Rider LG, Wu L, Mamyrova G, et al. Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2010;49:2381-90.
Dobloug GC, Svensson J, Lundberg IE, et al. Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis 2018;77:40-7.
Leclair V, Regardt M, Wojcik S, et al. Health-related quality of life (HRQoL) in idiopathic inflammatory myopathy: a systematic review. PLoS One 2016;11:e0160753.
Dobloug C, Garen T, Bitter H, et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis 2015;74:1551-6.
Lilleker JB, Vencovsky J, Wang G, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis 2018;77:30-9.

Auteurs

Léa Debrut (L)

UR3072 Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg, France.

Margherita Giannini (M)

UR3072 Centre de Recherche en Biomédecine, Université de Strasbourg, and Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Delphine Klein (D)

INSERM UMR-S1113, Registre des cancers du Bas-Rhin, Fédération de Médecine Translationnelle, Université de Strasbourg, Strasbourg, France.

Lionel Spielmann (L)

Service de rhumatologie, Centre Hospitalier de Colmar, Colmar, France.

Philippe Mertz (P)

Service de rhumatologie, Centre de Référence des Maladies Autoimmunes Rares (RESO), Hôpitaux Universitaire de Strasbourg, Strasbourg, France.

Thierry Martin (T)

Service de médecine interne, RESO, Hôpitaux Universitaire de Strasbourg, Strasbourg, France.

Aleksandra Nadaj-Pakleza (A)

Service de neurologie, Centre de Référence des Maladies Neuro-musculaires, Hôpitaux Universitaire de Strasbourg, Strasbourg, France.

Sandrine Hirschi (S)

Service de pneumologie, Centre de Compétence des Maladies Pulmonaires Rares, Hôpitaux Universitaire de Strasbourg, Strasbourg, France.

Benoit Nespola (B)

Laboratoire d'immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Béatrice Lannes (B)

Département de pathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Joëlle Terzic (J)

Service de pédiatrie, Centre de compétence des rhumatismes inflammatoires et maladies auto-immunes systémiques rares de l'enfant (RAISE), Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Olivier Hinschberger (O)

Service de médecine interne, Centre de Compétence des Maladies Auto-immunes Rares, Centre Hospitalier de Colmar, Colmar, France.

Benjamin Dervieux (B)

Service de médecine interne, Centre de Compétence des Maladies Auto-immunes Rares, Centre Hospitalier de Mulhouse, Mulhouse, France.

Dan Lipsker (D)

Service de dermatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Laurent Arnaud (L)

Service de rhumatologie, Centre de Référence des Maladies Autoimmunes Rares (RESO), Hôpitaux Universitaire de Strasbourg, Strasbourg, France.

Jacques-Eric Gottenberg (JE)

Service de rhumatologie, Centre de Référence des Maladies Autoimmunes Rares (RESO), Hôpitaux Universitaire de Strasbourg, Strasbourg, France.

Jean François Kleinmann (JF)

Service de rhumatologie, Centre de Référence des Maladies Autoimmunes Rares (RESO), Hôpitaux Universitaire de Strasbourg, Strasbourg, France.

Bernard Geny (B)

UR3072 Centre de Recherche en Biomédecine, Université de Strasbourg, and Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

François Séverac (F)

Pôle de Santé Publique, Secteur Méthodologie et Biostatistiques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Michel Velten (M)

INSERM UMR-S1113, Registre des cancers du Bas-Rhin, Fédération de Médecine Translationnelle, Université de Strasbourg, Strasbourg, France.

Jean Sibilia (J)

Service de rhumatologie, Centre de Référence des Maladies Autoimmunes Rares (RESO), Hôpitaux Universitaire de Strasbourg, Strasbourg, France.

Alain Meyer (A)

UR3072 Centre de Recherche en Biomédecine, Université de Strasbourg, Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, and Service de rhumatologie, RESO, Hôpitaux Universitaire de Strasbourg, Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH